Rifampin Adverse Effects
Infectious Disease
Illness script · Infectious Disease
Rifampin Adverse Effects
Broad-spectrum antimycobacterial drug notable for orange body-fluid discoloration, potent CYP450 induction, and hepatotoxicity.
This illness script for Rifampin Adverse Effects covers predisposing factors, classic presentation, mechanism, workup, management, and the clinical pivots that separate it from look-alikes—written for USMLE Step 1 and clerkship reasoning.
01
Predisposing factors
- Used in TB, leprosy, and meningococcal/H. influenzae prophylaxis
- Patients on polypharmacy (warfarin, OCPs, antiretrovirals, methadone) at high interaction risk
- Intermittent/high-dose regimens increase flu-like syndrome and thrombocytopenia risk
- Pre-existing liver disease increases hepatotoxicity risk
- Combined use with isoniazid and pyrazinamide is synergistically hepatotoxic
02
Presentation
- Orange-red discoloration of urine, tears, sweat, saliva — pathognomonic and benign
- Flu-like syndrome: fever, chills, myalgias — especially with intermittent dosing
- Jaundice, nausea, elevated LFTs — hepatotoxicity (can be severe in combo therapy)
- Purpura, bleeding — immune thrombocytopenia
- Drug interaction effects: OCP failure (unintended pregnancy), subtherapeutic warfarin, ART failure
03
Pathophysiology
- Potent inducer of CYP3A4, 2C9, 2C19 — accelerates metabolism of co-administered drugs
- Rifampin metabolites excreted in bile, urine, tears → orange-red pigmentation of all body fluids
- Hepatocellular toxicity via reactive metabolite formation, especially in combination regimens
- Intermittent dosing generates anti-rifampin antibodies → immune-mediated thrombocytopenia and flu-like reactions
04
Diagnostics
- Baseline LFTs, CBC, and bilirubin before initiating therapy
- Monitor LFTs monthly — hold if >3–5× ULN with symptoms
- Check drug interactions for ALL co-medications via CYP3A4 induction
- Soft contact lens staining by tears is irreversible — warn patients preemptively
- No specific rifampin drug level monitoring routinely used
05
Management
- Orange discoloration: reassurance only — no dose change needed
- Hepatotoxicity: hold rifampin if symptomatic or LFTs >5× ULN; switch regimen
- Flu-like syndrome: convert to daily (not intermittent) dosing
- Thrombocytopenia: permanently discontinue rifampin
- Drug interactions: switch OCPs to barrier method; increase warfarin monitoring; adjust ART regimen
06
Clinical pivots
How to separate this script from the look-alikes that show up on exams and on the wards.
Isoniazid (INH) toxicity
INH causes peripheral neuropathy (B6 deficiency) and drug-induced lupus; rifampin causes orange discoloration and CYP induction — not INH.
Pyrazinamide (PZA) toxicity
PZA causes hyperuricemia/gout and is the dominant hepatotoxin in RIPE; rifampin's signature toxicity is CYP induction and orange discoloration.
Ethambutol toxicity
Ethambutol causes optic neuritis with red-green color blindness; rifampin does not affect vision.
Viral hepatitis
Drug-induced hepatitis from rifampin has clear temporal relation to drug initiation and resolves with discontinuation, unlike acute viral hepatitis.
Keep reading
Full library- Pyloric StenosisHypertrophy of the pyloric muscle causing progressive gastric outlet obstruction in infants, typically 2–8 weeks of age.
- Rocky Mountain Spotted FeverTick-borne illness caused by Rickettsia rickettsii presenting with fever, headache, and centripetal rash involving palms and soles.
Educational use only. This illness script is a study framework, not medical advice. Confirm decisions with current guidelines and your clinical supervisors.